The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardised clinical care are essential for improving prognosis. Diagnosis of the disease requires a combination of clinical performance, imaging, laboratory testing and pathological activation.
A comprehensive assessment platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PET. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.